Back to today’s briefing

Story perspectives

Pfizer Beats Earnings Estimates Despite COVID Revenue Drop

11/4/2025

35 3 Full Breakdown

Summary

Story summary

Pfizer Inc. reported third-quarter 2025 adjusted earnings of 87 cents per share, beating the 63-cent consensus.
Revenue declined 6% year over year to $16.65 billion as demand for COVID-19 products, including Paxlovid, fell 55%.
Despite the decline, Pfizer raised its fiscal 2025 earnings guidance to $3.00–$3.15 per share and reaffirmed a $61–$64 billion sales outlook.
The stock was trading around $24.48 in premarket activity after falling nearly 1%.

1 of 1

Story summary

Pfizer Inc. reported third-quarter 2025 adjusted earnings of 87 cents per share, beating the 63-cent consensus.
Revenue declined 6% year over year to $16.65 billion as demand for COVID-19 products, including Paxlovid, fell 55%.
Despite the decline, Pfizer raised its fiscal 2025 earnings guidance to $3.00–$3.15 per share and reaffirmed a $61–$64 billion sales outlook.
The stock was trading around $24.48 in premarket activity after falling nearly 1%.